Baseline Patient Characteristics
| Characteristic | Data |
|---|---|
| Total patients | 32 |
| Age (y) | 69 (66–73) |
| ECOG | |
| 0 or 1 | 25 (78) |
| 2 | 7 (22) |
| Prior systemic treatments | |
| LHRH agonist/antagonist | 32 (100) |
| Chemotherapy | 32 (100) |
| Docetaxel | 32 (100) |
| Cabazitaxel | 29 (91) |
| Androgen signaling inhibitor | 32 (100) |
| Sites of disease | |
| Lymph nodes | 18 (56) |
| Bone | 30 (94) |
| Viscera | 6 (19) |
| Median PSMA tumor volume at screening (cm3) | 670 (275–1,736) |
| Number of cycles of 177Lu-PSMA-617 received | 6 (3–6) |
LHRH = luteinizing hormone-releasing hormone.
Qualitative data are absolute counts and percentage; continuous data are median and interquartile range.